![Anti-EGFR [2F8 (Zalutumumab; HuMax-EGFR)], Human IgG1](/skin/notimg.webp)
-
Anti-EGFR [2F8 (Zalutumumab; HuMax-EGFR)], Human IgG1
Anti-EGFR [2F8 (Zalutumumab; HuMax-EGFR)], Human IgG1
- 中文名称：
- Anti-EGFR [2F8 (Zalutumumab; HuMax-EGFR)], Human IgG1
- 英文名称：
- Anti-EGFR [2F8 (Zalutumumab; HuMax-EGFR)], Human IgG1
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA72270
- 规格：
- 0.2 mg|2x0.2 mg|3x0.2 mg|4x0.2 mg|5x0.2 mg
- 保存建议：
- Store at 4 degree C for up to 3 months. For longer storage, aliquot and store at -20 degree C.
- 货期：
- 6-8周
- 来源宿主：
- Human
- 反应种属：
- Human
- 应用：
- WB (Western Blot), ELISA, FCM/FACS (Flow Cytometry)
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 其他：
克隆性:N/A
同型:Human IgG1, Kappa
克隆号:[2F8 (Zalutumumab; HuMax-EGFR)]
特异性:This antibody binds domain III of the human epidermal growth factor receptor (EGFR).
纯度:Protein A affinity purified
形式：PBS with 0.02% Proclin 300.
浓度：1mg/ml
- 说明书：
This antibody blocks the binding of EGF and TGF-alpha to the EGFR. At saturating concentrations, 2F8 completely blocked EGF-R signaling and inhibited the in vitro proliferation of EGF-R-overexpressing A431 cells. At much lower concentrations, associated with low receptor occupancy, 2F8 induced efficient Ab-dependent cell-mediated cytotoxicity (ADCC) in vitro. In vivo studies showed potent antitumor effects in models with A431 tumor xenografts in athymic mice. Flow cytometry was used to analyze the binding of mAb 2F8 to EGFR overexpressing A431 cells. mAb 2F8 was found to bind to membrane-associated EGF-R with an EC50 of approximately 1 ug/ml (7 nM). The ability of mAb 2F8 to block ligand-induced receptor phosphorylation was determined using immunoblotting. ELISA was used to determine whether mAb 2F8 had a functional C1q binding cite (Bleeker et al., 2004). Phase I/II clinical trials and pharmacokinetic studies in patients with advanced squamous cell carcinoma of the head and neck revealsed that 2F8/HuMax-EGFR can be safely administered in doses upto 8 mg/kg (Bastholt et al., 2007) Antibody 2F8 binds the domain III of the EGFR and locks it into a very compact and inactice conformation. Biochemical analyses showed bivalent binding of 2F8 to provide potent inhibition of EGFR signaling (Beuren et al., 2008). EGFRvIII?specific CDC was significantly enhanced when zalutumumab was combined with a Fc?engineered variant of antibody MR1?1 (Klausz et al., 2011).
